Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors

Hypoxia is prominent in solid tumors and a recognized driver of malignancy. Thus far, targeting tumor hypoxia has remained unsuccessful. Myo-inositol trispyrophosphate (ITPP) is a re-oxygenating compound without apparent toxicity. In preclinical models, ITPP potentiates the efficacy of subsequent ch...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Schneider, Marcel A., Linecker, Michael, Fritsch, Ralph, Muehlematter, Urs J., Stocker, Daniel, Pestalozzi, Bernhard, Samaras, Panagiotis, Jetter, Alexander, Kron, Philipp, Petrowsky, Henrik, Nicolau, Claude, Lehn, Jean-Marie, Humar, Bostjan, Graf, Rolf, Clavien, Pierre-Alain, Limani, Perparim
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8217170/
https://ncbi.nlm.nih.gov/pubmed/34155211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-24069-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados